Comparison of Aerosolized Swallowed Fluticasone to Esomeprazole for the Treatment of Eosinophilic Esophagitis

Moawad, Fouad J.; Dias, Johnny A; Veerappan, Ganesh R.; Baker, Thomas; Maydonovitch, Corinne; Wong, Roy

doi:10.14309/00000434-201110002-00030

“…Those treated with budesonide had an improvement in symptoms related to dysphagia that was not seen in the placebo group. Several other studies of fluticasone and budesonide for treatment of EoE in adults have used the Mayo Dysphagia Questionnaire‐30 Day (MDQ‐30) to assess dysphagia . Although the MDQ‐30 was developed and validated for peptic strictures, none of the previously used measures have been validated for use in EoE, and as far as we are aware, none went through a development phase in a manner consistent with the FDA guidance on PROs…”

Section: Discussionmentioning

confidence: 99%

Development and field testing of a novel patient-reported outcome measure of dysphagia in patients with eosinophilic esophagitis

Dellon

¹

,

Irani

²

,

Hill

³

et al. 2013

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…This was first reported in a case series by Ngo and colleagues, and since then a number of studies have reported that one third or more of patients with esophageal eosinophilia have a response to PPIs. [72][73][74][75][76][77] This phenomenon has been termed PPI-REE. 1 It is not currently known whether this is a distinct clinical entity, a sub-type of GERD, or phenotype of EoE, but it's role must currently be addressed in the diagnostic algorithm for EoE.…”

Section: Diagnostic Dilemmasmentioning

confidence: 99%

Eosinophilic Esophagitis

Hirano¹,

Dellon²

2021

The Esophagus

1

0

View full text Add to dashboard Cite

Eosinophilic esophagitis (EoE) is a chronic immune-mediated condition where infiltration of eosinophils into the esophageal mucosa leads to symptoms of esophageal dysfunction. It has rapidly emerged as an important cause of upper GI morbidity in patients of all ages and is encountered in a substantial proportion of patients undergoing diagnostic upper endoscopy. This review discusses the clinical, endoscopic, and histologic features of EoE and presents the most recent guidelines for diagnosis of EoE. It describes selected diagnostic dilemmas including distinguishing EoE from gastroesophageal reflux disease and addressing the newly recognized clinical entity of proton pump inhibitor responsive esophageal eosinophilia. It also highlights evidence to support both pharmacologic and non-pharmacologic treatments, including topical corticosteroids, dietary elimination therapy, and endoscopic dilation.

show abstract

“…This was first reported in a case series by Ngo and colleagues, and since then a number of studies have reported that one third or more of patients with esophageal eosinophilia have a response to PPIs. [72][73][74][75][76][77] This phenomenon has been termed PPI-REE. 1 It is not currently known whether this is a distinct clinical entity, a sub-type of GERD, or phenotype of EoE, but it's role must currently be addressed in the diagnostic algorithm for EoE.…”

Section: Diagnostic Dilemmasmentioning

confidence: 99%

Eosinophilic Esophagitis

Reed

¹

,

Dellon

²

2019

Evidence‐based Gastroenterology and Hepatology 4e

View full text Add to dashboard Cite

Eosinophilic esophagitis (EoE) is a chronic immune-mediated condition where infiltration of eosinophils into the esophageal mucosa leads to symptoms of esophageal dysfunction. It has rapidly emerged as an important cause of upper GI morbidity in patients of all ages and is encountered in a substantial proportion of patients undergoing diagnostic upper endoscopy. This review discusses the clinical, endoscopic, and histologic features of EoE and presents the most recent guidelines for diagnosis of EoE. It describes selected diagnostic dilemmas including distinguishing EoE from gastroesophageal reflux disease and addressing the newly recognized clinical entity of proton pump inhibitor responsive esophageal eosinophilia. It also highlights evidence to support both pharmacologic and non-pharmacologic treatments, including topical corticosteroids, dietary elimination therapy, and endoscopic dilation.

show abstract

Comparison of Aerosolized Swallowed Fluticasone to Esomeprazole for the Treatment of Eosinophilic Esophagitis

Cited by 7 publications

References 0 publications

Development and field testing of a novel patient-reported outcome measure of dysphagia in patients with eosinophilic esophagitis

Development and field testing of a novel patient-reported outcome measure of dysphagia in patients with eosinophilic esophagitis

Eosinophilic Esophagitis

Eosinophilic Esophagitis

Contact Info

Product

Resources

About